Thursday, October 15th at 15:00 GMT | 16:00 CEST | 10:00 EST | 07:00 PST
Differences between human in vitro findings, animal in vivo studies and clinical observations can leave safety teams with a difficult question: where is the discrepancy coming from?
In this webinar, Silke Schwengberg of Ncardia will discuss how non-human primate (NHP) iPSC-derived cardiomyocytes can be used to retrospectively investigate differences between experimental systems and provide additional biological context when results do not align.
She will be joined by Sonja Stölzle-Feix, Director of Scientific Affairs at Nanion Technologies, who will present preliminary findings generated with Ncardia’s NHP cardiomyocytes and discuss what these observations may contribute to the interpretation of translational differences.
The session will explore where NHP iPSC-derived models can add value, what questions they can help address, and how their findings can be interpreted alongside human iPSC models, animal studies, and clinical observations.
Key learning objectives
- Where translational differences arise
- When an NHP iPSC model can help
- How to investigate discordant findings
- Where the model has limitations
Who should attend?
This webinar is intended for scientists and decision-makers working in:
- preclinical and translational safety
- cardiac safety pharmacology
- toxicology
- human iPSC-based safety assessment
- nonclinical programme strategy
- interpretation of discordant preclinical and clinical findings
Register for the webinar
When findings across experimental systems do not align, understanding why can be as important as the individual result.
Join Silke and Sojna to explore how NHP iPSC-derived cardiomyocytes can help investigate translational differences and add context to an existing body of safety data.
Speakers
Silke holds a PhD in cell biology and immunology from the University of Hannover, Germany, and has over 20 years of experience in stem cell-based models for drug discovery. She is passionate about developing and applying functional iPSC cardiomyocyte assays to assess the efficacy and safety of novel drug therapies. Before joining Ncardia, Silke led cross-functional teams at stem-cell technology companies and worked as an independent scientific consultant for eight years, providing expertise in assay development for drug discovery and toxicology. At Ncardia, Silke applies her extensive experience to advance innovative toxicology solutions, supporting the development of safer and more effective therapeutics.
-1.svg)
Sonja has been at Nanion Technologies since 2005; she currently serves as Director of Scientific Affairs in Munich, Germany. She has been involved in the CiPA ion channel and myocyte working groups since 2016, and earned her PhD at the University of Würzburg, conducting research in molecular plant physiology and biophysics under Prof. Dr. R. Hedrich. She is also the author of more than 30 scientific publications covering automated patch clamping, cell physiology, and cardiac safety.
